Skip to main content

Peer Review reports

From: A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial

Original Submission
19 Jun 2020 Submitted Original manuscript
22 Jun 2020 Reviewed Reviewer Report - Kirsty Loudon
Resubmission - Version 2
Submitted Manuscript version 2
Publishing
22 Jun 2020 Editorially accepted
13 Jul 2020 Article published 10.1186/s13063-020-04548-z

You can find further information about peer review here.

Back to article page